ACIS was able to launch a scientific research project with Harbour Laboratory at Bascom Palmer, Miami. Phase One of the research is complete, with findings pointing to significant differences between “variants” of the two mutations believed to be the initiating mutations leading to Ocular Melanoma, GNAQ and GNA11. Now in the second phase, the lab will be using a new approach to identify candidate therapeutic targets. More information on this trial should be out in early 2020 when a phase 2 study will open and more funding will be needed. With your partnership, we can invest in more research to hopefully see A Cure In Sight.